AbbVie reports SKYRIZI and RINVOQ data in inflammatory bowel disease
New data for SKYRIZI (risankizumab-rzaa) and RINVOQ (upadacitinib) demonstrate disease control for patients living with inflammatory bowel disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.